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Abstract
Objective—This study sought to determine the frequency of possible cardiopulmonary drug-drug 
interactions among pregnant women who received intrapartum magnesium sulfate (MgSO4).
Methods—Pregnant women admitted to an Intermountain Healthcare facility between January 
2009 and October 2011 were studied if they received one or more doses of MgSO4. Concomitant 
medications were electronically queried from an electronic health records system. Adverse events 
were identified using administrative discharge codes. The frequency of cardiopulmonary drug-
drug interactions was compared among women who did, and did not, receive aminoglycoside 
antibiotics, antacids / laxatives, calcium channel blockers, corticosteroids, diuretics, 
neuromuscular blocking agents, and vitamin D analogs, all of which are contraindicated for 
patients receiving MgSO4.
Results—Overall, 683 women received intrapartum MgSO4 during the study period. A total of 
219 MgSO4 potentially interacting drugs were identified among 155 (23%) unique patients. The 
most commonly identified potentially interacting agents included calcium channel blockers (26%), 
diuretics (25%), and antacids / laxatives (19%). Longer hospital stays were significantly 
associated with increasing numbers of MgSO4 interacting drugs (P<0.001). Three of 53 (6%) 
women who received furosemide experienced a cardiac arrest, compared to 0 of 618 (0%) women 
who did not receive furosemide (Fisher’s Exact Test P<0.001).
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Conclusion—Intrapartum administration of drugs that interact with MgSO4 is common and 
associated with prolonged hospital stays and potentially cardiopulmonary drug-drug interactions. 
Caution is warranted when prescribing MgSO4 in combination with known interacting 
medications.
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INTRODUCTION
Magnesium sulfate (MgSO4) is currently used in pregnancy for prevention and treatment of 
pre-eclampsia and eclampsia, and more recently, for fetal neuroprophylaxis prior to preterm 
birth. While a Cochrane Review of women at risk of preterm birth who received MgSO4 
demonstrated a neuroprotective effect for the fetus,1 the United States Food and Drug 
Administration (FDA) recently revised MgSO4 prescription drug labels to indicate that there 
is “positive evidence of human fetal risk when the drug is used during pregnancy.”2 This 
change was prompted following a review of the published literature in which 18 cases of 
skeletal abnormalities were reported among neonates exposed to MgSO4 for a mean 
duration of 10 weeks.3–6 The recently updated FDA guidelines now caution that MgSO4 
should not be used for more than 7 days to prevent pre-term labor.2 Although MgSO4 has 
been used historically to prevent pre-term labor,7 several randomized controlled trials have 
now confirmed that it is ineffective as a tocolytic.8–11
Many adverse events can result from MgSO4 administration. One of the most serious is the 
neuromuscular blockade which can be observed on a continuum from diminished deep 
tendon reflexes to somnolence to flaccid paralysis.12 The diaphragm and other respiratory 
muscles may also be affected and cause respiratory compromise.12 It has long been 
recognized that MgSO4 administration alters maternal calcium metabolism when used alone 
or when used concurrently with calcium-channel blockers such as nifedipine.13 Magnesium 
also acts as a calcium channel antagonist, and therefore, can cause bradycardia, hypotension, 
electrocardiogram changes (i.e., P–Q interval prolongation and widened QRS complex), and 
at very high levels, cardiac arrest.14 Hypocalcemia can also result from MgSO4 therapy by 
inhibition of parathyroid hormone.15 The potential also exists for severe and/or prolonged 
respiratory depression which can result from the concomitant use of aminoglycoside 
antibiotics and other neuromuscular blocking agents.16,17 Many other drugs and drug classes 
have been identified that interact with MgSO4, which can result in an increased 
pharmacological effect or increased risk of magnesium toxicity, both of which increase the 
potential for adverse events.18
The extent to which pregnant women receiving MgSO4 are simultaneously exposed to 
potentially-interacting drugs is unknown. In this study, the prescribing patterns of 
concomitant drugs were evaluated along with the frequency with which pregnant women 
were exposed to MgSO4 and one or more potentially-interacting drugs. As a secondary 
Campbell et al. Page 2













objective, the frequency of cardiopulmonary drug-drug interactions and their impact upon 
clinical outcomes were examined.
MATERIALS AND METHODS
Ethics approval
Ethical approval was granted for this retrospective chart review study. This study was 
reviewed and granted a waiver of informed consent by the University of Utah and 
Intermountain Healthcare Institutional Review Boards.
Study design
Pregnant women who were hospitalized and received intravenous MgSO4 at an 
Intermountain facility from January of 2009 through October 2011 were identified. Patients 
receiving one or more doses of MgSO4 were included in this study. Demographics, 
concomitant medications given ± 48 hours from MgSO4 administration, and clinical 
outcomes were obtained electronically by querying Intermountain’s electronic data 
warehouse system.
Magnesium sulfate dosing
Standardized MgSO4 administration protocols are used at Intermountain facilities. 
Typically, a standard loading dose of 4–6 grams was infused over 15–30 minutes, followed 
by 1–2 grams/hour administered as a continuous infusion. This standardized dosing regimen 
may differ slightly between the 17 institutions studied and whether treatment was for 
preeclampsia/eclampsia and/or fetal neuroprophylaxis. MgSO4 administration was not 
targeted to achieve a specific therapeutic range; however, patients were monitored for signs 
and symptoms of toxicity.19
Assessment of cardiopulmonary drug-drug interactions
The adverse effects of MgSO4 have primarily been attributed to its action as a smooth 
muscle relaxant.20 At high serum magnesium levels (>15 mEq/L) cardiac arrest and acute 
respiratory failure have been reported.21 Cardiopulmonary adverse events were identified in 
this population of pregnant women using International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9) discharge diagnosis codes. Patients with cardiac 
arrest and acute respiratory failure were initially identified using ICD-9 codes (427.5 and 
511.81, respectively) and their medical records were then manually reviewed to confirm the 
diagnosis.
Statistical methods
Descriptive statistics were used to calculate the number of MgSO4 drug-drug interactions. 
Drug interactions classified as ‘major’ or ‘moderate’ according to a clinical significance 
classification algorithm featured on Drugs.com were evaluated in this study.18 This 
classification scheme incorporates data from Micromedex™, Cerner Multum™, and Wolters 
Kluwer™ and was current as of 18 June 2013.
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A generalized logistic regression model with a categorical number / extent-of-interactions 
term was used to evaluate the influence of MgSO4 drug-drug interactions upon total hospital 
length of stay. Pairwise t-tests were used to assess the significance of the drug-drug 
interaction upon the mean hospital length of stay. Categorical variables were compared 
using the χ2 test or Fisher’s exact test, as appropriate. All statistical analyses were performed 
in Stata 11.2 (StataCorp, College Station, TX) and R 3.0.1 (R Foundation for Statistical 
Computing, Vienna, Austria).
RESULTS
Demographic and clinical characteristics
Overall, 683 women received intravenous MgSO4 over the study period. Of these, 130 
(19%) received MgSO4 for the treatment of mild or not-otherwise-specified pre-eclampsia. 
Severe pre-eclampsia was documented as the primary indication for treatment in 341 (50%) 
cases and eclampsia in 8 (1%) cases. There were 267 (39%) diagnosed with early-onset 
delivery. Diagnosis of both pre-eclampsia / eclampsia and early-onset delivery was common 
and occurred in 210 (31%) of these cases. The mean age of these women was 27.4 (standard 
deviation (SD) ± 5.6) years (Table 1). Most women had singleton pregnancies (96%) and 
delivered at a mean gestational age of 35.5 (± 3.2) weeks. Newborn weights ranged from 
680 to 5520 (mean 2546) grams.
Interacting medications
A total of 219 MgSO4 drug-drug interactions were identified among this cohort of pregnant 
women. At least one MgSO4 drug-drug interaction was detected for 155 (23%) unique 
patients (Table 2). As shown in Figure 2, the majority of MgSO4 drug interactions occurred 
among women who were concomitantly prescribed calcium channel blockers (e.g., 
nifedipine), diuretics (e.g., furosemide), and antacids / laxatives (e.g., magnesium 
hydroxide). A minority (2%) received the aminoglycoside agent gentamicin, which has been 
reported to potentiate the neuromuscular blocking activity of magnesium (Table 3).17
Adverse drug-drug interactions
A cardiopulmonary adverse event occurred among 13 of 155 (8%) women who received one 
or more MgSO4 interacting drugs. None of the 531 women who did not receive an 
interacting drug experienced a cardiopulmonary adverse event (Fisher’s Exact test P<0.001). 
Twelve of the 13 (92%) cardiopulmonary adverse events were documented among pregnant 
women who simultaneously received a diuretic agent. The most commonly identified 
diuretic was furosemide, which accounted for 11 (85%) of the cardiopulmonary adverse 
drug-drug interactions. Three of 53 (6%) women who received furosemide with MgSO4 
experienced a cardiac arrest as compared to 0 of 618 who did not receive furosemide 
(Fisher’s Exact test P<0.001). Additionally, 9 (17%) furosemide-treated women developed 
acute respiratory failure as compared to 2 of 618 (0.3%) women who did not receive 
furosemide (Fisher’s Exact Test P<0.001).
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Women who were prescribed one or more potentially MgSO4 interacting drugs delivered 
earlier (mean gestational age 35 vs. 36 weeks; P=0.01) and gave birth to newborns with 
lower birth weights (mean 2400 vs. 2587 grams; P=0.01). Additionally, maternal hospital 
stays were prolonged among women who had a MgSO4 drug-drug interaction identified 
(Figure 2). Among women who received intrapartum MgSO4 without the concomitant 
administration of a potentially interacting medication the mean hospital length of stay was 
3.4 (± 2.5) days, as compared to 4.7 (± 5.6) days among women who were prescribed one 
potentially interacting drug and 7.8 (± 14.0) days among women who received two or more 
potentially interacting drugs (P<0.001 for all).
COMMENT
Pregnant women are frequently prescribed MgSO4 with one or more concomitant 
medications that are known to interact and have the potential to result in toxicity.22 The 
most commonly prescribed classes of MgSO4 interacting drugs included diuretics, calcium 
channel blockers, and antacids / laxatives. Women who received a MgSO4 interacting drug 
had longer hospital stays and a lower gestational age at delivery. Concomitant 
administration of the diuretic agent furosemide was associated with higher rates of cardiac 
arrest and acute respiratory failure.
Acute or chronic hypertensive disorders affect up to 8% of pregnant women in the United 
States.23 Complications of pre-eclampsia, including severe hypertension requiring 
pharmacotherapy and major fluid imbalances that cause cerebral or pulmonary edema, 
typically occur within the first two weeks after delivery.24 Orally administered diuretics, 
such as furosemide, are thought to decrease the need for antihypertensive therapies, reduce 
the incidence of side effects, and shorten hospital stays.25 However, laxatives may potentiate 
the pharmacological effects of diuretics.26 MgSO4 can cause significant fluid and electrolyte 
loss, the effects of which may be additive to those of diuretics.27 Metabolic imbalances – 
including the depletion of sodium, potassium, magnesium, and zinc – may occur and have 
been associated with heart failure and cardiac arrhythmias.28,29 In this study, it was found 
that the concomitant administration of MgSO4 and furosemide was associated with an 
increased risk of cardiopulmonary adverse events, which may have occurred as a 
consequence of profound fluid loss and electrolyte imbalances.
Other commonly identified MgSO4 interacting drugs included calcium channel blockers and 
antacids / laxatives. Calcium channel blockers are routinely used to treat pregnancy-induced 
hypertension; however, guidelines from the National Heart Lung and Blood Institute advise 
clinicians to avoid concomitantly administering calcium channel blockers and MgSO4 on 
the basis of two case reports that described two cases of severe maternal hypotension and 
two cases of transient neuromuscular blockade.30–32 In this study, nearly 1 in 10 pregnant 
women simultaneously received MgSO4 and a calcium channel blocker and two (4%) 
experienced a cardiopulmonary drug-drug interaction. Several case reports have described 
iatrogenic magnesium overdoses resulting in cardiac conduction delays, asystole, apnea, and 
coma following the concomitant administration of MgSO4 and another magnesium-
containing antacid / laxative.33,34 Although pregnancy results in a physiologic increase in 
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renal function,35 more than 1 in 20 pregnant women in this study contemporaneously 
received MgSO4 and another magnesium-containing antacid / laxative. In this population, 
close clinical monitoring for signs and symptoms of magnesium toxicity is warranted.
The interpretation of this study’s findings is subject to several limitations. First, we have 
reported an association between several drugs that are known to interact with MgSO4 and 
their impact upon clinical outcomes, however due to the observational retrospective design 
of this study we cannot determine causality nor control for concurrent illness or disease 
severity. Therefore, we cannot rule out that the clinical differences described herein are not 
secondary to drug-drug interactions. Clinical caution is therefore warranted when 
considering the use of these drugs concurrently.36 Second, the use of ICD-9 discharge codes 
may lead to misclassification of adverse drug-drug interactions; however, medical records 
were manually reviewed for each of the patients who had an ICD-9 code for cardiac arrest or 
acute respiratory failure and they were found to feature 100% agreement. Furthermore, in a 
separate control cohort of 299 women who received intrapartum furosemide alone over the 
same timeframe, none experienced a cardiac arrest or an episode of acute respiratory failure. 
Lastly, it was not possible to associate number of maternal MgSO4 doses with the 
development of adverse events, although this warrants future study.
The concomitant administration of MgSO4 and other drugs known to result in adverse drug 
interactions is common among pregnant women. The number of MgSO4 drug-drug 
interactions was associated with both longer hospital stays and lower gestational age at 
delivery. Moreover, several women experienced cardiac arrest and acute respiratory failure. 
MgSO4 drug-drug interactions occurred most frequently among patients receiving 
concomitant diuretics, calcium channel blockers, and antacids / laxatives. All obstetric care 
providers should be aware of these cardiopulmonary drug-drug interactions and consider 
prescribing non-interacting medications when alternative therapies are available.
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Drug classes identified in magnesium sulfate (MgSO4) drug-drug interactions among 
hospitalized pregnant women.
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Total hospital length of stay among women who received intrapartum magnesium sulfate 
(MgSO4) by the number and type of identified drug-drug interactions. White circles 
represent mean values and black bars indicate 95% confidence intervals. Major drug-drug 
interactions were classified according to the drug interaction classification scheme featured 
on Drugs.com.18
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Table 1
Demographic and clinical characteristics of the 683 women who received intrapartum magnesium sulfate and 
their newborn infants.
Maternal characteristics at the time of delivery Mean (± SD)
 Age (yrs) 27.4 (± 5.6)
 Height (cm) 165.2 (± 17.6)
 Pre-pregnancy weight (kg) 74.5 (± 20.6)
 Current weight (kg) 88.5 (± 20.5)
 Estimated weight gain/loss during pregnancy (kg) 13.9 (± 8.1)
 Estimated body mass index (BMI) at time of delivery 32.6 (± 7.5)
Maternal race / ethnicity Number (%)
 American Indian / Alaskan Native 9 (1%)
 Asian 12 (2%)
 Black 8 (1%)
 Hispanic 108 (16%)
 Pacific Islander 16 (2%)
 White 517 (76%)
 Other 4 (1%)
 Unknown / Not reported 9 (1%)
Maternal diagnoses * Number (%)
 Mild pre-eclampsia / not otherwise specified 130 (19%)
 Severe pre-eclampsia 341 (50%)
 Eclampsia 8 (1%)
 Early-onset delivery 267 (39%)
 Early-onset delivery plus Pre-eclampsia / eclampsia 210 (31%)
Monitoring of magnesium serum concentrations Number (%)
 Mothers with one concentration measured 673 (99%)
 Median (range; IQR) concentrations measured/patient 2 (1–18; IQR 1–3)
 Mean ± SD of 1st concentrations measured 5.0 ± 1.9 mg/dL
Newborn characteristics
 Gestational age at delivery, weeks 35.5 (± 3.2)
 Birthweight, grams 2,546 (± 792)
*
Sums to more than 100% due to patients with multiple overlapping diagnoses (e.g., pre-eclampsia and early-onset delivery).
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Table 2
Frequency of identified drug interactions among pregnant women receiving magnesium sulfate (MgSO4).
Total number of patients receiving MgSO4 683 (100%)
Patients with one or more drug-drug interaction(s) 155 (23%)
 MODERATE* (Moderately Significant) Interaction 142 (21%)
  1 Interacting drug 105 (15%)
  2 Interacting drugs 25 (4%)
  3 Interacting drugs 10 (1%)
  4 Interacting drugs 1 (<1%)
  5 Interacting drugs 1 (<1%)
 MAJOR* (Highly Significant) Interaction 13 (2%)
  1 MAJOR interacting drug 4 (1%)
  1 MAJOR and 1 MODERATE interacting drug 6 (1%)
  1 MAJOR and 2 MODERATE interacting drugs 3 (<1%)
*
Moderate and major drug-drug interactions were classified according to the drug interaction classification featured on Drugs.com.18 Data sources 
include Micromedex™, Cerner Multum™, Wolters Kluwer™ and others.
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